fluoropyrimidine, HER2-tabbatacce, oxaliplatin, Seagen Inc., tucatinib, Tukysa
An ba da izini ga gaggawa ta FDA zuwa tucatinib tare da trastuzumab don ciwon daji na launi
A cikin Fabrairu 2023, Hukumar Abinci da Magunguna (FDA) ta haɓaka amincewar tucatinib (Tukisa, Seagen Inc.) da trastuzumab don kula da RAS daji mai nau'in HER2 mai cutar kansa wanda ya yaɗu ko kuma ba zai iya zama rem ba.